Rallybio Corp — Investor Relations & Filings
Filings indexed
246
across all filing types
Latest filing
2026-05-13
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
RLYB
Rallybio Corp. is a clinical-stage biotechnology company that develops and commercializes therapies for patients with severe and rare diseases. The company's development pipeline focuses on complement dysregulation and hematology. Key programs include RLYB116, a C5 inhibitor being investigated for complement-mediated diseases, and a therapy for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Rallybio operates with a portfolio-based model, identifying and accelerating the development of assets such as small molecules and engineered proteins to address significant unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Rallybio Corp (0001739410) (Filer) | 2026-05-13 | English | |
| 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | |
| S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | |
| 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | |
| 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 45759935 | 10-Q - Rallybio Corp (0001739410) (Filer) | 2026-05-13 | English | ||
| 40888387 | 8-K - Rallybio Corp (0001739410) (Filer) | 2026-05-04 | English | ||
| 36271286 | S-4/A - Rallybio Corp (0001739410) (Filer) | 2026-04-24 | English | ||
| 32897547 | 8-K - RALLYBIO CORP (0001739410) (Filer) | 2026-03-02 | English | ||
| 32897544 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-24 | English | ||
| 32897545 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-21 | English | ||
| 32897546 | 4 - RALLYBIO CORP (0001739410) (Filer) | 2026-02-20 | English | ||
| 31541794 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31541795 | 8-K Filing | 2026-01-29 | English | ||
| 13111487 | DEF 14A | 2026-01-02 | English | ||
|
2025
5 filings
| |||||
| 13111488 | PRE 14A | 2025-12-23 | English | ||
| 13111490 | 10-Q | 2025-11-06 | English | ||
| 13111494 | 8-K | 2025-11-06 | English | ||
| 13111491 | 8-K | 2025-08-29 | English | ||
| 13111493 | 10-Q | 2025-08-07 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
MYND Life Sciences Inc.
Developing CNS treatments using novel psychedelic and neuro…
|
MYND | CA | Professional, scientific and te… |
|
MyndTec Inc.
Develops neurotechnology products for improving function in…
|
MYTC | CA | Professional, scientific and te… |
|
N4 PHARMA PLC
Develops a silica nanoparticle delivery system for nucleic …
|
N4P | GB | Professional, scientific and te… |
|
NanHua Bio-medicine CO.,Ltd．
Develops cell-based therapies, regenerative medicine, and s…
|
000504 | CN | Professional, scientific and te… |
|
Nanjing Leads Biolabs Co., Ltd.
Clinical-stage biotech discovering and developing innovativ…
|
9887 | HK | Professional, scientific and te… |
|
NanoGroup S.A.
Develops nanotechnology-based medical solutions for oncolog…
|
NNG | PL | Professional, scientific and te… |
|
NANO MRNA Co.,Ltd.
Biotechnology firm creating and out-licensing IP for mRNA-b…
|
4571 | JP | Professional, scientific and te… |
|
NanoSphere Health Sciences Inc.
Nano-biotechnology firm creating advanced drug delivery sys…
|
NSHS | CA | Professional, scientific and te… |
|
NANOVIRICIDES, INC.
Clinical-stage biopharma developing broad-spectrum, nanomed…
|
NNVC | US | Professional, scientific and te… |
|
Natcore Technology Inc.
R&D entity using nanotechnology to improve solar cell effic…
|
NTCXF | CA | Professional, scientific and te… |
Rallybio Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34901/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34901 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34901 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34901 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34901}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Rallybio Corp (id: 34901)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.